Artemisinin News and Research

RSS
Artemisinin is a drug used to treat multi-drug resistant strains of falciparum malaria. The compound (a sesquiterpene lactone) is isolated from the plant Artemisia annua. Not all plants of this species contain artemisinin.
U.N. General Assembly passes resolution urging renewed efforts to fight malaria

U.N. General Assembly passes resolution urging renewed efforts to fight malaria

iOWH's semisynthetic ART enters production, distribution phase to combat malaria

iOWH's semisynthetic ART enters production, distribution phase to combat malaria

Artemisinin or high-pressure oxygen can boost natural cancer remedy

Artemisinin or high-pressure oxygen can boost natural cancer remedy

Government of Canada commits to contribute towards global effort to combat malaria

Government of Canada commits to contribute towards global effort to combat malaria

Anacor Pharma, MMV enter agreement to develop AN3661 for malaria treatment

Anacor Pharma, MMV enter agreement to develop AN3661 for malaria treatment

Anacor and iOWH establish research agreement to identify new drugs for shigellosis

Anacor and iOWH establish research agreement to identify new drugs for shigellosis

Tropical seaweed's antifungal chemical cues may have promising antimalarial properties for humans

Tropical seaweed's antifungal chemical cues may have promising antimalarial properties for humans

Advocates call for follow-through on decade-old pledge to remove tariffs on malaria treatments, prophylactics in Africa

Advocates call for follow-through on decade-old pledge to remove tariffs on malaria treatments, prophylactics in Africa

NBC News examines drug-resistant malaria along Thai-Cambodian border

NBC News examines drug-resistant malaria along Thai-Cambodian border

News outlets examine reaction to WHO plan to contain drug-resistant malaria

News outlets examine reaction to WHO plan to contain drug-resistant malaria

WHO, Roll Back Malaria partnership launch initiative to contain artemisinin-resistant malaria

WHO, Roll Back Malaria partnership launch initiative to contain artemisinin-resistant malaria

Drug resistant malaria on the prowl

Drug resistant malaria on the prowl

The Scientist examines how nonprofit, for-profit pharma groups are working together to make drugs more affordable for developing countries

The Scientist examines how nonprofit, for-profit pharma groups are working together to make drugs more affordable for developing countries

WHO report shows significant progress in global malaria fight, highlights need for continued funding

WHO report shows significant progress in global malaria fight, highlights need for continued funding

Global Fund to draw up action plan against drug theft, invites stakeholders to participate

Global Fund to draw up action plan against drug theft, invites stakeholders to participate

Emergency artesunate suppositories are cost-effective intervention for children with suspected severe malaria

Emergency artesunate suppositories are cost-effective intervention for children with suspected severe malaria

One-third of malaria-endemic countries are complying with WHO malaria drug efficacy monitoring standards, report says

One-third of malaria-endemic countries are complying with WHO malaria drug efficacy monitoring standards, report says

National monitoring essential for preventing emergence of malaria drug resistance

National monitoring essential for preventing emergence of malaria drug resistance

New malaria drug can save millions of lives: Study

New malaria drug can save millions of lives: Study

NBER project identifies and analyzes African successes

NBER project identifies and analyzes African successes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.